Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 14 at 2:00 PM EDT

Register Free →

This Solicitation opportunity from Department Of Defense was posted on October 1, 2025. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Biological Technologies

Closed
HR001126S0003Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714
New
Federal
Pre-solicitation Notice: On-Ramp for the Department of Defense OMNIBUS IV Multiple-Award Contract
Solicitation # HT942626RE002
The Defense Health Agency Contracting Activity is issuing a pre-solicitation notice for an on-ramp to the OMNIBUS IV Multiple Award, Indefinite Delivery, Indefinite Quantity (IDIQ) contract vehicle. This initiative aims to expand the pool of eligible contractors providing military medical research and development services, including laboratory and technical support, regulatory process expertise, and translational science services. The eventual Request for Proposal will be set aside exclusively for small businesses certified under the Small Business Administration 8(a) Program. Due to the need to implement recent FAR Overhaul guidance, the anticipated posting timeframe for the solicitation has been extended to late September 2026. The OMNIBUS IV vehicle operates with a base ordering period from June 20, 2022, through June 19, 2027, and an option ordering period extending to June 19, 2032. It features a cumulative ceiling of 10 billion dollars, with over 630 million dollars already awarded across 55 task orders to various end users, including the Naval Supply Systems Command and the Uniformed Services University of the Health Sciences. New awards from this on-ramp will align with the existing unrestricted vehicle. Prospective offerors must be registered in SAM.gov and will be required to submit proposals through the Procurement Integrated Enterprise Environment solicitation module once the formal RFP is released.
Defense Health Agency

POSTED

about 20 hours ago

DEADLINE

N/A
NAICS: 541714
New
Federal
Biobanking, Laboratory Analytics, and Associated Informatics Services for NIH Biorepositories
Solicitation # 75N98026R00175
The National Institutes of Health is issuing a Sources Sought Notice to identify qualified research and development firms, small businesses, and subcontractors capable of providing biobanking, laboratory analytics, and informatics services for NIH biorepositories starting in fiscal year 2028. The primary objective is to support the operation and potential consolidation of repositories, specifically including the NIDA Center for Genetic Studies and the NIH Brain Development Cohorts Biobank. This is a market research effort to determine the availability of technically capable sources and to inform the government's decision on the appropriate acquisition method and potential small business set-asides. The required scope of work involves the secure storage and tracking of at least 3.5 million biospecimens, comprehensive data curation and management using auditable LIMS, and advanced laboratory capabilities such as high-throughput sequencing and CRISPR/Cas9 gene editing. Additionally, the contractor must provide informatics support to develop and maintain web portals, APIs, and secure cyberinfrastructure compliant with FISMA standards. Interested parties must submit a detailed capability statement, including experience, personnel qualifications, and facility descriptions, to the designated contract specialists by October 20, 2026.
National Institutes Of Health Nida

POSTED

2 days ago

DEADLINE

in 17 days
NAICS: 541714
New
Federal
Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS)
Solicitation # ARPA-H-SOL-26-164
The Advanced Research Projects Agency for Health (ARPA-H) is soliciting proposals for the Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) program under solicitation ARPA-H-SOL-26-164. This five-year initiative aims to create a reusable blueprint for future adaptive seamless platform trials through the integration of three technical areas: a Phaseless Design Engine, Continuous Inference, and Agentic Operations. The program is divided into two stages, with Stage I focusing on capability buildout, FDA engagement, and the onboarding of at least three intervention arms over 24 months, followed by a 36-month Stage II dedicated to validation and deployment. A critical go/no-go milestone is obtaining FDA authorization for the platform Master Protocol IND and at least one investigational arm by the end of Stage I. The government intends to make multiple awards via Other Transaction Agreements to proposers offering the most advantageous solutions based on innovation, feasibility, and technical merit at reasonable prices. Eligible entities must possess a Unique Entity Identifier and active SAM registration. Proposals are submitted in a phased approach, beginning with a Solution Summary and potentially progressing to a Solution Pitch package. Performance will be measured by the successful integration of the three technical areas and the achievement of specific program metrics. All work must adhere to ICH E6(R3) Good Clinical Practice and strict regulatory standards to ensure inspection readiness and participant safety.
Advanced Research Projects Agency For Health (arpa-H)

POSTED

3 days ago

DEADLINE

in about 2 months
NAICS: 541714
New
Federal
SURPASS Webinar and Proposers' Day Information
Solicitation # ARPA-H-SN-26-164
The Advanced Research Projects Agency for Health (ARPA-H), under the Department of Health and Human Services, has issued Special Notice ARPA-H-SN-26-164 regarding the Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) program. This initiative aims to modernize clinical research by transforming drug and biologics development into a continuous learning system, with the goal of reducing development timelines from over ten years to fewer than four. The program focuses on creating disease-specific multi-arm platforms that integrate AI-powered operational infrastructure, in silico modeling, and advanced adaptive designs to enable a seamless transition from first-in-patient evaluation to confirmatory assessment. Key outputs include a reusable blueprint for future trials, simulation-based design tools, and continuous inference and adaptation approaches, all aligning with the goals of HHS Operation TrialBlazer. This specific notice serves as an informational announcement and does not constitute a formal solicitation for proposals. It invites interested parties to an informational webinar on October 15, 2026, and a two-day Proposers Day on November 6 and 9, 2026. Potential participants may optionally submit teaming profiles, lightning talk slides, and posters to showcase their expertise. Full program details and formal solicitation requirements are located under solicitation ARPA-H-SOL-26-164. All inquiries are directed to the SURPASS team, with Daria Fedyukina serving as the Technical Point of Contact.
Advanced Research Projects Agency For Health (arpa-H)

POSTED

3 days ago

DEADLINE

in 10 days
NAICS: 541714
Federal
ARPA-H Comprehensive Organ System Modeling in Outer Space (COSMOS) Innovative Solutions Opening
Solicitation # ARPA-H-SOL-26-165
The Advanced Research Projects Agency for Health (ARPA-H) is seeking proposals under solicitation ARPA-H-SOL-26-165 for the Comprehensive Organ System Modeling in Outer Space (COSMOS) initiative. This program aims to determine if microgravity in Low Earth Orbit (LEO) accelerates tissue aging across brain, cardiac, uterine, and kidney tissues compared to terrestrial rates. If the Tissue Aging Rate in Space (TARIS) is found to significantly exceed the Tissue Aging Rate on Earth (TAROE), the initiative intends to establish a high-throughput, autonomous drug screening platform in LEO to make biomedical research and development more cost-effective and faster than Earth-based methods. The project is structured into two sequential phases: a 27-month Phase I focused on establishing and validating microphysiological systems (MPS) to quantify aging rates, and a 15-month Phase II dedicated to developing age-related pathology models for pro-regenerative drug testing. Key requirements include the use of MPS or organoids for at least 75 percent of experimental samples, the creation of LEO twin experiments, and the establishment of a contractual partnership with at least one Fortune 100 biopharmaceutical company. The program schedule spans FY27 through FY30 and includes two planned space launches in months 39 and 41. Awards will be granted via multiple Other Transaction (OT) Agreements to the most advantageous proposers, including universities, non-profits, and businesses. Evaluation is based primarily on the innovation and feasibility of the technical approach, the potential to transform biomedicine, and the team's expertise in managing costs and schedules. Proposers must adhere to strict administrative requirements, including the BIOSECURE Act, NIH Genomic Data Sharing policies, and specific research security and cybersecurity disclosures. Full proposals are due by October 7, 2026.
Advanced Research Projects Agency For Health (arpa-H)

POSTED

8 days ago

DEADLINE

in 4 days
NAICS: 541714
Federal
ARPA-H Emerging Health Innovators (EHI) Initiative
Solicitation # ARPA-H-SOL-26-150
The Advanced Research Projects Agency for Health (ARPA-H) Emerging Health Innovators (EHI) initiative, solicitation ARPA-H-SOL-26-150, is a mentorship program designed to identify and engage early-career investigators for cutting-edge biomedical, health, and community-engaged research. Eligible principal investigators must be within eight years of completing their first terminal degree. The program focuses on 16 specific topic areas and utilizes a two-step submission process, beginning with an anonymized solution summary due October 30, 2026, followed by full proposals due February 10, 2027. Awards are issued as Other Transaction (OT) agreements with a tentative start date of June 30, 2027. Each award has a total value not to exceed 1,050,000 dollars over a three-year period, consisting of a two-year base period capped at 700,000 dollars and an optional third year capped at 350,000 dollars. Funding is structured around a fixed-price milestone payment schedule, with 12 total quarterly milestones and payments processed through the Payment Management Services (PMS) system. Performance is monitored via monthly one-hour virtual reviews with the ARPA-H program team. Evaluation is based on technical merit, innovativeness, feasibility, and alignment with the ARPA-H mission, with a strong emphasis on risk mitigation and the potential to impact national health research.
Advanced Research Projects Agency For Health (arpa-H)

POSTED

8 days ago

DEADLINE

in 4 months
NAICS: 541714
Grant
NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)
Solicitation # PAR-28-072
The National Institutes of Health National Eye Institute is offering a bi-phasic, milestone-driven award through the Translational Research Program for Therapeutics (PAR-28-072) to accelerate the transition of laboratory research into biological, pharmaceutical, or medical device therapies for visual system diseases. The program is structured into two phases: an R61 phase of up to two years focusing on preliminary data and lead optimization, and an R33 phase of up to four years dedicated to final preclinical development and the filing of an Investigational New Drug or Investigational Device Exemption application with the FDA. The total combined duration of both phases cannot exceed five years. Transition to the R33 phase is contingent upon the administrative assessment of satisfactory completion of SMART milestones, which must include required pre-submission feedback from the FDA. Budgetary limits for direct costs are generally capped at 500,000 dollars per year for the R61 phase and 1,000,000 dollars per year for the R33 phase. Applicants must provide a Target Product Profile, a Gantt chart, and an Intellectual Property Strategy, while ensuring compliance with Good Manufacturing Practices and Good Laboratory Practice standards. Evaluation is based on the importance of the research, rigor and feasibility of the approach, and the expertise of the investigators and their environment. Eligible applicants, including small businesses and other for-profit organizations, must maintain active registrations in the System for Award Management and eRA Commons, and all principal investigators must have a linked ORCID ID. Awardees are also required to implement cybersecurity incident reporting procedures and an incident response plan in accordance with HHS guidelines.
National Institutes Of Health

POSTED

8 days ago

DEADLINE

in about 3 years

AI Contract Overview

Show more

The Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO) has issued Broad Agency Announcement HR001126S0003 to solicit transformative research proposals that leverage biological properties and processes to enhance warfighter protection. The solicitation focuses on high-impact science, specifically targeting areas such as artificial intelligence and machine learning for biological modeling, novel bio-inspired materials and sensors, combat casualty care, human performance optimization, and agricultural or environmental security. Research that offers only evolutionary improvements to existing practices is explicitly excluded. DARPA intends to award projects through various instruments, including procurement contracts, cooperative agreements, and Other Transaction Agreements for both research and prototypes. Proposers must follow a multi-stage submission process, beginning with a mandatory two-page abstract submitted via the Broad Agency Announcement Tool (BAAT). If invited, full proposals must be submitted by September 30, 2026, with technical and management volumes limited to 20 pages. For procurement contracts and Other Transactions, submissions must be made through BAAT, while cooperative agreements are submitted via Grants.gov. Evaluation criteria prioritize scientific and technical merit, relevance to the DARPA mission, and cost and schedule realism. The solicitation includes provisions for an accelerated award option for efforts not exceeding $2,000,000 and mandates strict compliance with Controlled Unclassified Information (CUI) protections and cybersecurity requirements. All cost proposals must utilize the provided DARPA Streamlined Cost Proposal Spreadsheet to ensure traceability and rapid analysis.

General Info

DARPA BTO seeks transformative biological research proposals for warfighter protection and human performance.

Documents

14

Contract HR00112CXXX Accelerated Baseline Model Small Business

PDF, High priority: read this firstcontract-document
High

Contract HR00112CXXX Award Document

PDF, High priority: read this firstcontract-document
High

DARPA BTO Broad Agency Announcement HR001126S0003 Biological Technologies

PDF, High priority: read this firstbaa
High

HR001126S0003 Abstract Submission Template for Biological Technologies BAA

DOCX, High priority: read this firstabstract-template
High

HR001126S0003 Attachment C Volume II Cost Proposal Instructions and Template

DOCX, High priority: read this firstcost-proposal-template
High

HR001126S0003 Attachment G Accelerated Award Option Election and Attestation Form

DOCX, High priority: read this firstattachment
High

HR001126S0003 Baseline Model Contract Addendum

DOCX, High priority: read this firstcontract-document
High

HR001126S0003 Biological Technologies Proposal Instructions and Volume I Template

DOCX, High priority: read this firstproposal-instructions-template
High

HR001126S0003 Classified Submission Instructions

DOCX, High priority: read this firstsubmission-instructions
High

HR001126S0003 Cooperative Agreement V2

DOCX, High priority: read this firstcooperative-agreement
High

HR001126S0003 DARPA Model Other Transaction Agreement for Prototype

DOCX, High priority: read this firstcontract-document
High

HR001126S0003 DARPA Streamlined Cost Proposal Spreadsheet V3

XLSX, High priority: read this firstcost-proposal-spreadsheet
High

HR001126S0003 Model Other Transaction Agreement for Research

DOCX, High priority: read this firstcontract-document
High

HR001126S0003 Controlled Unclassified Information Guide

PDF, Low priorityother
Low

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

PhaseClosed
Posted

Solicitation

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Darpa - Biological Technologies Office
Contacts1 person available
OfficeUSA
Office AddressUSA
Contacts
DARPA - Biological Technologies Office

Full Description

Show more
The Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO) is soliciting proposals that leverage biological properties and processes to revolutionize our ability to protect the nation’s warfighters. Specifically excluded is research that primarily results in evolutionary improvements to the existing state of practice.

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS